IND 11

Efficacy, Safety, and Tolerability of NKTR-181 in Patients With Moderate to Severe Chronic Low-Back Pain: A Phase 3 Study

John Markman,[1] Jeffrey Gudin,[2] Richard Rauck,[3] Charles Argoff,[4] Michael Rowbotham,[5] Eva Agaiby,[6] Joseph Gimbel,[7] Nathaniel Katz,[8] Stephen K. Doberstein,[9] Mary Tagliaferri,[9] Lin Lu,[9] John Silowsky,[9] Suresh Siddhanti,[9] Martin Hale[10]

[1]University of Rochester School of Medicine and Dentistry, Rochester, NY; [2]Englewood Hospital and Medical Center, Englewood, NJ; [3]Carolinas Pain Institute and The Center for Clinical Research, Winston-Salem, NC; [4]Albany Medical College, Albany, NY; [5]California Pacific Medical Center Research Institute, San Francisco, CA; [6]Clinical Investigation Specialists Inc, Kenosha, WI; [7]Arizona Research Center, Phoenix, AZ; [8]Tufts University School of Medicine, Boston, MA; [9]Nektar Therapeutics, San Francisco, CA; [10]Gold Coast Research, LLC, Plantation, FL

SUMMIT-07

NEKTAR

Introduction

- Opioid analgesics are commonly used in the treatment of chronic pain; however, their use is limited by poor tolerability and a high prevalence of abuse and drug-related mortality.[1-3] Although abuse-deterrent formulations have been developed, FDA-approved options include only conventional opioid agonists combined with opioid antagonists or with tamper-resistant reformulations. In patients with poorly-controlled chronic pain on non-opioid analgesics, there remains a great unmet need for safer opioid medication.[4]
- NKTR-181, a new molecular entity, is a full mu-opioid receptor (MOR) agonist currently in development for the treatment of chronic low back pain in adult patients new to opioid therapy.[5] NKTR-181 was designed to have a reduced rate of entry into the central nervous system (CNS) compared with standard opioids, thereby reducing a key pharmacokinetic risk factor related to potential for euphoria and abuse.[5] The slowed rate of CNS entry observed with NKTR-181 is inherent to its molecular structure and defies alteration by physical, chemical, or thermal means into a rapid-acting MOR agonist. In a recent study of recreational opioid users, patient-reported drug-high and drug-liking scores for NKTR-181 administered as single doses of 100 to 400 mg were lower than those for oxycodone and closely resembled placebo.[6] Additionally, pupillometry data confirmed a delayed onset of a CNS effect associated with NKTR-181.[6]
- Here we present the results of SUMMIT-07, a phase 3, enriched-enrollment, randomized-withdrawal study which evaluated the analgesic efficacy, safety, and tolerability of NKTR-181 administered at 100 to 400 mg twice daily to opioid-naïve patients with chronic moderate-to-severe low-back pain, the most common indication for opioid analgesics in the United States.

Methods

- SUMMIT-07 compared NKTR-181 and placebo in opioid-naïve adult patients with moderate to severe chronic, non-neuropathic, low-back pain of at least 6-month duration, for which non-opioid analgesia had been inadequate. This enriched-enrollment, randomized-withdrawal study included a screening period, an open-label titration period, and a double-blind, placebo-controlled treatment period lasting 12 weeks **(Figure 1)**.

Figure 1. Study Design



- Throughout the study, patients scored their daily pain on an 11-point numerical rating scale ranging from 0 ("No pain") to 10 ("Pain as bad as you can imagine"). For inclusion, a patient's 7-day average score at the end of screening was required to be 5 to 9 points. Among eligible patients, open-label NKTR-181 initiated at 100 mg twice daily could be increased to a maximum of 400 mg twice daily. Patients achieving a 7-day average pain score of ≤4 points, representing a decrease of ≥2 points, were randomized to double-blind treatment with NKTR-181 per patient dose or placebo.
- The study's primary efficacy endpoint was change in weekly pain score at the end of the double-blind, randomized treatment period (week 12) relative to the baseline pain score. Key secondary endpoints included the percentage of responders with week-12 pain scores ≥30% and ≥50% lower than their screening score, the percentage of adverse events (AEs) and treatment-emergent AEs (TEAEs), and the percentage of patients reporting improvement on the Patient Global Impression of Change (PGIC) scale. Sleep quality was evaluated using the Medical Outcomes Study (MOS) Sleep Scale-Revised. Assessments of study-drug safety and tolerability included the frequency of reported AEs.

References

1. Ballantyne JC. *Pain.* 2015;156(4):567–568;
2. Centers for Disease Control and Prevention (CDC). *MMWR.* 2016;64(50):1378–1382;
3. Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. *Ann Intern Med.* 2015;162(4):276–286;
4. Becker WC, Fiellin DA. *N Engl J Med.* 2017;376(22):2103–2105;
5. Miyazaki T, Choi IY, Rubas W, et al. *J Pharmacol Exp Ther.* 2017. doi:10.1124/jpet.117.243030;
6. Webster L, Henningfield J, Buchhalter AR, et al. *Pain Med.* 2017. doi:10.1093/pm/pnw344.

Results

- Out of 1,189 patients exposed to NKTR-181 during the open-label titration period, the intention-to-treat (ITT) population consisted of 610 patients randomized to receive NKTR-181 (n=309) or placebo (n=301). Their baseline characteristics are summarized in **Table 1**.

Table 1. Patients' Characteristics By Randomized Treatment Group (ITT Population)

Characteristic	NKTR-181 Group (N=309)	Placebo Group (N=301)
Age (years)		
Mean (SD)	52.0 (12.7)	50.7 (12.5)
Range	20–74	20–75
Sex, n (%)		
Female	187 (60.5%)	170 (56.5%)
Male	122 (39.5%)	131 (43.5%)
Race, n (%)		
White	205 (66.3%)	196 (65.1%)
Black	95 (30.7%)	93 (30.9%)
Other	9 (2.9%)	12 (4.0%)
BMI (kg/m^2), mean (SD)	30.5 (5.4)	30.5 (5.1)[a]
Time since LBP onset (years), mean (SD)	13.3 (10.0)	13.0 (9.8)
Pain score,[b] mean (SD)		
At screening	6.70 (0.98)	6.76 (0.91)
At baseline[c]	2.29 (1.08)	2.35 (1.09)
MOS Sleep Scale–Revised scores at screening, mean (SD)		
Sleep disturbance	47.8 (23.7)[d]	47.8 (23.1)[a]
Sleep problems	42.2 (18.4)[d]	42.7 (18.0)[a]
Respiratory impairments	25.4 (21.4)[d]	26.4 (21.6)[a]
Sleep adequacy	48.1 (23.1)[d]	46.7 (23.1)[a]
Daytime sleepiness (somnolence)	32.5 (20.1)[d]	33.7 (20.8)[a]
Sleep quantity (hrs/night)	6.0 (1.2)[d]	5.8 (1.2)[a]

[a]N=300; [b]Seven-day average of daily scores on an 11-point numerical rating scale ranging from 0 ("No pain") to 10 ("Pain as bad as you can imagine"); [c]The end of open-label NKTR-181 titration, immediately preceding randomization; [d]N=307.
BMI, body mass index; ITT, intention-to-treat; LBP, low-back pain; MOS, Medical Outcomes Study; SD, standard deviation.

- Among randomized patients, the least-squares mean change from randomization baseline in weekly pain score after 12 weeks of double-blind treatment was +0.92 points for NKTR-181 vs +1.46 points for placebo, indicating a statistically significant analgesic effect in patients randomized to NKTR-181 (P=0.0019).
- Mean weekly pain scores at screening, at baseline, and during randomized treatment are displayed in **Figure 2**.

Figure 2. Mean Weekly Pain Scores[a] at Screening, at Baseline,[b] and During Randomized Treatment (ITT Population)



The difference between treatment groups was statistically significant at week 1 and at all subsequent weeks (P<0.0001 at all weeks).

[a]Seven-day average of daily scores on an 11-point numerical rating scale ranging from 0 ("No pain") to 10 ("Pain as bad as you can imagine");
[b]The end of open-label NKTR-181 titration, immediately preceding randomization.
ITT, intention-to-treat; NRS, numeric rating scale.

- Use of rescue medication in NKTR-181 patients was less than placebo throughout the randomized treatment period.
- The distribution of percent reduction in pain score at 12 weeks is presented in **Figure 3**.

Figure 3. Cumulative Distribution of Percent Reduction in Pain Score at 12 Weeks (ITT Population)[a]



Patients in the NKTR-181 vs the placebo group reported a reduction ≥30% from pre-treatment scores by 71.2% and 57.1% (P=0.0003), respectively, and a reduction ≥50% by 51.1% and 37.9% (P=0.001), respectively.

**P<0.01, ***P<0.001 vs placebo.
[a]Patients discontinued before 12 weeks were counted as non-responders.
ITT, intention-to-treat.

- Patient responses on the PGIC scale are shown in **Figure 4**. A greater proportion of patients randomized to NKTR-181 characterized themselves as "Improved" or "Very much improved" at week 12 (51.5% vs 33.2%; P<0.0001).
- Changes from screening baseline in MOS Sleep Scale scores among observed cases at week 12 are summarized in **Table 2**. The differences between treatment groups showed statistically significant improvement in the domains of sleep disturbance (P<0.0001), sleep problems (P=0.0004), sleep adequacy (P=0.0015), and sleep quantity (P=0.0477) for NKTR-181 compared with placebo. Scores for daytime sleepiness (somnolence) and respiratory impairments were not statistically different between groups.

Figure 4. Patient Global Impression of Change (ITT Population)



ITT, intention-to-treat.

Table 2. Twelve-Week Change in MOS Sleep Scale–Revised Scores (Observed Cases)

LS Mean Change (SE)	NKTR-181 Group (N=254)	Placebo Group (N=253)
Negative change indicates improvement		
Sleep disturbance	–16.8 (1.3)***	–9.4 (1.3)
Sleep problems	–11.9 (1.0)***	–6.7 (1.0)
Positive change indicates improvement		
Sleep adequacy	+9.8 (1.4)**	+3.4 (1.4)
Sleep quantity (hrs/night)	+0.4 (0.1)*	+0.2 (0.1)
Comparability to placebo is preferred		
Respiratory impairments	–3.9 (1.1)	–1.8 (1.1)
Day-time sleepiness (somnolence)	–6.5 (1.2)	–7.0 (1.2)

*P<0.05; **P<0.01; ***P<0.001 vs placebo.
LS, least-squares; MOS, Medical Outcomes Study; SE, standard error.

- AEs during double-blind treatment were reported by 54.4% of the NKTR-181 group and 49.8% of the placebo group. The preferred terms reported by >5% of patients during the open-label titration phase and their corresponding incidence during the randomization phase for each treatment group are presented in Table 3.
- AEs commonly associated with opioid therapy such as somnolence, dizziness, and sedation were infrequent (2.6% vs 0.3%, 2.3% vs 0.3%, and 0.0% vs 0.3% during randomization for NKTR-181 and placebo, respectively).
- During double-blind treatment, AEs led to study discontinuation of 8.4% patients in the NKTR-181 group vs 3.0% patients in the placebo group.

Table 3. Adverse Events During Double-Blind Treatment[a]

Incidence, n (%)	Open-Label Titration	Double-Blind Treatment Period	
	NKTR-181 Group (N=1190)	NKTR-181 Group (N=309)	Placebo Group (N=301)
Constipation	425 (35.7%)	27 (8.7%)	9 (3.0%)
Nausea	176 (14.8%)	32 (10.4%)	18 (6.0%)
Daytime sleepiness (somnolence)	107 (9.0%)	8 (2.6%)	1 (0.3%)
Headache	83 (7.0%)	10 (3.2%)	14 (4.7%)
Vomiting	67 (5.6%)	15 (4.9%)	5 (1.7%)
Dry mouth	66 (5.6%)	7 (2.3%)	1 (0.3%)
Fatigue	61 (5.1%)	4 (1.3%)	1 (0.3%)

[a]The listing includes all preferred terms reported by ≥5.0% during open-label titration.

Conclusions

- In patients with moderate to severe chronic low-back pain, NKTR-181 administered at 100 to 400 mg twice daily showed statistically significant analgesia compared to placebo (P=0.0019).
- The percentage of responders with week-12 pain scores ≥30% and ≥50% lower than their screening score was significantly better for NKTR-181 than placebo (P=0.0003 and P=0.001, respectively).
- A greater proportion of patients (51.5% NKTR-181 vs 33.2% placebo; P<0.0001) reported their condition as "improved" to "very much improved" at week 12.
- NKTR-181 has a favorable safety and tolerability profile. Patients reported a lower incidence of CNS-related AEs such as somnolence (ie, daytime sleepiness), dizziness, and sedation than expected with conventional opioid therapies.
- NKTR-181, a full mu-opioid receptor agonist having a reduced rate of entry into the CNS when compared to conventional opioids, is an effective therapy for low-back pain and may address the unmet need for a safer opioid medication for the treatment of chronic low back pain in adult patients new to opioid therapy.

PRESENTED AT THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS 2018 NATIONAL CONFERENCE • JUNE 26–JULY 1, 2018 • DENVER, COLORADO

This study was funded by Nektar Therapeutics.